AA
TEVA icon

Armis Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Armis Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
45,883
+95
+0.2% +$3.16K 0.15% 114
2026
Q1 		$1.66M Buy
45,788
+50
+0.1% +$1.61K 0.16% 101
2025
Q4 		$1.31M Buy
+45,738
New +$1.13M 0.15% 111
2025
Q1 		– Sell
-10,241
Closed -$226K – 459
2024
Q4 		$226K Buy
+10,241
New +$186K 0.03% 328

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Armis Advisers's TEVA Position: Q2 2026 in Review

Armis Advisers increased its Teva Pharmaceuticals (TEVA) stake by 0.21% in Q2 2026, buying an estimated $3.16K and bringing the position to 45,883 shares worth $1.62M. The position accounts for 0.15% of the portfolio, ranked #114.

Armis Advisers first reported a position in TEVA in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.66M in Q1 2026. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Armis Advisers held 45,883 shares of Teva Pharmaceuticals worth $1.62M as of Q2 2026.
  • Armis Advisers bought 95 Teva Pharmaceuticals shares in Q2 2026, an estimated $3.16K.
  • Teva Pharmaceuticals made up 0.15% of Armis Advisers's portfolio in Q2 2026, its #114 holding.
  • Armis Advisers first reported a position in Teva Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Armis Advisers's Teva Pharmaceuticals position peaked at $1.66M in Q1 2026.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Armis Advisers's 13F filing for Q2 2026, filed 7 Jul 2026.